SCHEMBL4156879

SCHEMBL4156879

Cc1ccc(NC(=O)c2ccnc3[nH]c(-c4ccsc4)nc23)c(N)n1

nearest known ligand 0.46

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 6/20 0.46
MET P08581 1/20 0.41
IKBKE Q14164 1/20 0.39
TBK1 Q9UHD2 1/20 0.39
TOP2A P11388 1/20 0.37
GSK3A P49840 2/20 0.37
VCP P55072 1/20 0.36
HDAC1 Q13547 2/20 0.36
CDC7 O00311 1/20 0.36
CHEK2 O96017 2/20 0.35
WNT1 P04628 1/20 0.35
CDK5 Q00535 1/20 0.35
CDK5R1 Q15078 1/20 0.35
DHODH Q02127 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13778056 0.83 GSK3B (0.52) GSK3BMETIKBKETBK1GSK3A
SCHEMBL4159232 0.83 GSK3B (0.59) GSK3BMETIKBKETBK1GSK3A
SCHEMBL4161267 0.80 GSK3B (0.46) GSK3BMETIKBKETBK1GSK3A
SCHEMBL4152707 0.79 GSK3B (0.58) GSK3BMETIKBKETBK1GSK3A
SCHEMBL4153749 0.79 GSK3B (0.46) GSK3BMETGSK3ACHEK2WNT1
SCHEMBL4154179 0.77 GSK3B (0.58) GSK3BMETGSK3A
SCHEMBL4161109 0.77 DHODH (0.50) GSK3BMETTOP2AGSK3ACDC7
SCHEMBL4150197 0.77 GSK3B (0.75) GSK3BMETIKBKETBK1GSK3A
SCHEMBL4148138 0.77 GSK3B (0.53) GSK3BMETIKBKETBK1GSK3A
SCHEMBL4158223 0.77 PKN1 (0.49) GSK3BMETTOP2AGSK3ACDC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US claimed
EP-1984370-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Crystalgenomics, Inc. (KR) 2008-10-29 EP claimed
WO-2007083978-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME CRYSTALGENOMICS, INC. (KR) 2007-07-26 WO claimed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same GSK3B, GSK3A, MAP3K3 GSK3B 1/4885MET 1418/4885IKBKE 115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.